- ►ucsf.edu [PDF] JG McHutchison, SC Gordon, ER Schiff, ML … - New England Journal …, 1998 - content.nejm.org ABSTRACT Background Only 15 to 20 percent of patients with chronic hepatitis C have a sustained
virologic response to interferon therapy. We compared the ef- ficacy and safety of recombinant
interferon alfa-2b alone with those of a combination of interferon alfa- 2b and ribavirin for ... Cited by 2523 - Related articles - BL Direct - All 11 versions
JH Hoofnagle, AM Di Bisceglie - The New England Journal of …, 1997 - nejm.highwire.org Chronic viral hepatitis is the principal cause of chronic liver disease, cirrhosis, and hepatocellular
carcinoma in the world and now ranks as the chief reason for liver transplantation in adults. 1
, 2 , 3 Of the five known hepatitis viruses, three can cause persistent infection and chronic ... Cited by 861 - Related articles - All 4 versions
JH Hoofnagle - … Conference ON Management OF Hepatitis C - consensus.nih.gov 15 Hepatitis C: The Clinical Spectrum of Disease Jay H. Hoofnagle, MD The hepatitis C virus
(HCV) is an important cause of both acute and chronic hepatitis. As with all diseases, the clinical
course and outcome of hepatitis C are variable—there is no single natural history of ... Cited by 523 - Related articles - View as HTML - BL Direct - All 7 versions
- ►annals.org TJ Liang, B Rehermann, LB Seeff, JH … - Annals of internal …, 2000 - Am Coll Physicians Approximately 4 million persons in the United States and probably more than 100 million persons
worldwide are infected with hepatitis C virus. The virus has the unique ability to cause persistent
infection in susceptible hosts after parenteral or percutaneous transmission, and its ... Cited by 493 - Related articles - BL Direct - All 5 versions
BL Kasiske, CB Cangro, S Hariharan, DE … - American Journal of …, 2001 - pt.wkhealth.com These guidelines are designed to facilitate the evaluation of candidates for renal
transplantation. Although they are meant to be comprehensive, they cannot cover every possible
aspect of the evaluation. Each renal transplant candidate is different and each faces ... Cited by 355 - Related articles - BL Direct - All 3 versions
HC Bodenheimer Jr, KL Lindsay, GL Davis, JH … - Hepatology, 1997 - interscience.wiley.com Hepatitis C is a common cause of chronic liver disease that may progress to cirrhosis. We conducted
a multicenter double-blind placebo-controlled trial of ribavirin 600 mg given orally twice daily
for 36 weeks with follow-up off therapy for an additional 16 weeks. Fifty-nine patients with ... Cited by 290 - Related articles - BL Direct - All 3 versions
ME Cramp, S Rossol, S Chokshi, P Carucci, R Williams … - Gastroenterology, 2000 - Elsevier The mechanisms by which either IFN monotherapy or IFN+R bring about resolution of infection
remain poorly understood. IFN-α has direct antiviral effects and a number of immunomodulatory
activities that can enhance antiviral immune responses. 5 Ribavirin is a nucleoside ... Cited by 249 - Related articles - BL Direct - All 9 versions
- ►isa-geek.com [PDF] MG Ghany, DE Kleiner, H Alter, E Doo, F Khokar, K … - Gastroenterology, 2003 - medscape.com Liver fibrosis is a highly dynamic process in which multiple genes interact with environmental
factors. Recent human epidemiologic studies have identified possible polymorphisms in a number
of candidate genes that influence the progression of liver fibrosis. These genetic factors ... Cited by 245 - Related articles - BL Direct - All 5 versions
JJ Feld, JH Hoofnagle - Nature, 2005 - nature.com Since the identification of the hepatitis C virus, great strides have been made in the development
of an antiviral therapy. As a crucial mediator of the innate antiviral immune response,
interferon- (IFN- ) was a natural choice for treatment. Whereas treatment with IFN- alone ... Cited by 241 - Related articles - BL Direct - All 5 versions
DTY Lau, DE Kleiner, MG Ghany, Y Park, P Schmid, … - Hepatology, 1998 - interscience.wiley.com Sustained responses to interferon- occur in 10% to 25% of patients with chronic hepatitis C, but
the long-term outcome is not well defined. We evaluated the long-term clinical, histological, and
virological outcomes of 10 patients with chronic hepatitis C who were treated between ... Cited by 212 - Related articles - BL Direct - All 3 versions
